<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.95098</article-id><article-id pub-id-type="publisher-id">ACM-30278</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190500000_70572478.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  外泌体及其microRNA与帕金森病相关研究进展
  Research Advances in Exosome and Their MicroRNA for Parkinson’s Disease
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>白</surname><given-names>家赫</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郑</surname><given-names>亚利</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>于</surname><given-names>永鹏</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属威海市中心医院于永鹏创新工作室，山东 威海</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>09</day><month>05</month><year>2019</year></pub-date><volume>09</volume><issue>05</issue><fpage>650</fpage><lpage>656</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    帕金森病(Parkinson’s disease, PD)在神经系统退行性疾病中位于第二位，目前仍缺乏有效用于PD早期诊断的生物标志物，使众多PD患者错失了早诊断、早治疗的机会。外泌体及其microRNA对于PD等神经系统退行性疾病潜在的诊疗价值日益成为研究的热点，有望成为PD早期诊断的标志物。本文从外泌体及其microRNA的起源、特性，参与PD发生发展的过程，对PD的早期预警、诊断及靶向治疗等方面进行综述，以期为临床及科研工作提供新的思路。
    Parkinson’s disease (PD) is the second in the degenerative diseases of the nervous system. It still lacks biomarkers for early diagnosis of PD, which makes many PD patients miss the opportunity of early diagnosis and treatment. The potential value of exosome and their microRNA for the diagnosis and treatment of neurodegenerative diseases such as PD has become a research hotspot, and it is expected to become a biomarker for early diagnosis of PD. This article reviews the origin and characteristics of exosomes and their microRNA, and participates in the development of PD, the early warning, diagnosis and targeted treatment of PD, in order to provide new ideas for clinical and scientific research. 
  
 
</p></abstract><kwd-group><kwd>帕金森病，外泌体，微RNAs, Parkinson’s Disease</kwd><kwd> Exosomes</kwd><kwd> MicroRNAs</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>外泌体及其microRNA与帕金森病 相关研究进展<sup> </sup></title><p>白家赫<sup>1,2,3</sup>，郑亚利<sup>1,2,3</sup>，于永鹏<sup>1,2,3*</sup></p><p><sup>1</sup>青岛大学附属威海市中心医院于永鹏创新工作室，山东 威海</p><p><sup>2</sup>青岛大学附属威海市中心医院神经内科，山东 威海</p><p><sup>3</sup>威海市自体免疫重点实验室，山东 威海</p><disp-formula id="hanspub.30278-formula57"><graphic xlink:href="//html.hanspub.org/file/4-1570934x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年4月25日；录用日期：2019年5月13日；发布日期：2019年5月20日</p><disp-formula id="hanspub.30278-formula58"><graphic xlink:href="//html.hanspub.org/file/4-1570934x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>帕金森病(Parkinson’s disease, PD)在神经系统退行性疾病中位于第二位，目前仍缺乏有效用于PD早期诊断的生物标志物，使众多PD患者错失了早诊断、早治疗的机会。外泌体及其microRNA对于PD等神经系统退行性疾病潜在的诊疗价值日益成为研究的热点，有望成为PD早期诊断的标志物。本文从外泌体及其microRNA的起源、特性，参与PD发生发展的过程，对PD的早期预警、诊断及靶向治疗等方面进行综述，以期为临床及科研工作提供新的思路。</p><p>关键词 :帕金森病，外泌体，微RNAs</p><disp-formula id="hanspub.30278-formula59"><graphic xlink:href="//html.hanspub.org/file/4-1570934x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/4-1570934x8_hanspub.png" /> <img src="//html.hanspub.org/file/4-1570934x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>PD是第二大神经系统变性病，是中老年人致残的重要疾病。随着人口的老龄化，PD患者数量将进一步增加，为了对帕金森病进行早期诊断，我国2016年对PD诊断标准进行更新，将嗅觉减退及心脏去交感神经支配等一些生物标志物也纳入到诊断标准当中。由于PD在疾病早期症状不典型，且易与多系统萎缩、进行性核上性麻痹等疾病相混淆。因此，当前对于PD早期诊断仍然是一个难题。对于PD患者来说，往往陷入一旦确诊即进入中晚期的困境。</p><p>外泌体是一种直径约30~100 nm膜性小囊泡，是细胞间信号转导的重要载体，具有丰富的可检测靶标(蛋白、DNA、miRNA、脂质等)。MicroRNA (miRNA)是长度为18~24个核苷酸的内源性单链短序列非蛋白编码RNAs，参与了大约30%基因的表达，并参与细胞生成、分化、增殖和凋亡等多种细胞过程的调节，其异常调节会导致神经变性疾病和癌症多种疾病的发生 [<xref ref-type="bibr" rid="hanspub.30278-ref1">1</xref>] 。研究 [<xref ref-type="bibr" rid="hanspub.30278-ref2">2</xref>] 表明，外泌体由于体积小，可透过血脑屏障从中枢神经系统转移至体循环，并且外泌体由于具备脂质双膜结构能抵抗血液中核糖核酸酶的攻击，miRNA在体液中有高度稳定性、分泌选择性，还有其易于检测的特点，提示体液中外泌体所携带的miRNA可能更真实地反映颅内情况，2018年美国神经学年会上报道外泌体诊断PD具有高度敏感性和特异性，更提示其具备作为帕金森病早期诊断生物标志物和靶向治疗PD的潜力。</p></sec><sec id="s4"><title>2. 外泌体及其microRNA生理功能及特性</title><p>外泌体从内体发展而来，内体又形成包含腔内囊泡(ILV)的多囊体(MVB)。然后，MVB与各种细胞类型的细胞膜融合，以作为外泌体释放细胞的ILV，它们的产生可以由许多因素诱导，包括细胞外刺激、微生物攻击、其他压力条件等，外泌体的功能取决于来源的细胞或组织，通过转运蛋白质、脂质、DNA、mRNA和miRNA等物质调节受体细胞的功能 [<xref ref-type="bibr" rid="hanspub.30278-ref3">3</xref>] 。外泌体中的部分miRNA例如mir-14、mir-23等 [<xref ref-type="bibr" rid="hanspub.30278-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.30278-ref5">5</xref>] ，可在细胞分化、代谢，组织发育过程中起调控作用，因为miRNA可通过与靶mRNA的3’端非翻译区相结合，促进靶mRNA降解或抑制其翻译，故外泌体及其microRNA参与了神经系统变性疾病的发生发展。此外，外泌体还有以下诸多特性 [<xref ref-type="bibr" rid="hanspub.30278-ref6">6</xref>] ：第一，外泌体几乎可从每个细胞中分离，包括真核、原核细胞。第二，外泌体参与调节正常生物过程，例如免疫反应，血凝等。第三，外泌体涉及到神经退行性疾病、肿瘤等常见疾病的病理生理机制。第四，细胞可特异性捕获外泌体并利用其传递信息，第五，它们在体内(全身循环)和体外都是非常稳定的(经长时间冷冻保存而不会破坏其生物学特性)。</p></sec><sec id="s5"><title>3. 外泌体及其miRNA参与PD发生发展</title><p>α–突触核蛋白是路易小体的主要成分，其异常聚集是PD的主要核心病理改变，预测减少α–突触核蛋白表达会减缓PD的发生发展，而外泌体可能为促进α–突触核蛋白异常聚集提供关键环境。研究发现PD患者脑脊液(CSF)的外泌体与正常者相比更能够诱导α–突触核蛋白的寡聚化 [<xref ref-type="bibr" rid="hanspub.30278-ref7">7</xref>] 。Danzer等人 [<xref ref-type="bibr" rid="hanspub.30278-ref8">8</xref>] 利用蛋白片段互补试验不仅证明了外泌体中含有寡聚化α–突触核蛋白，还发现外泌体α–突触核蛋白相对于游离α–突触核蛋白传递物质的效率更高，为了进一步了解外泌体在α–突触核蛋白聚集中的作用，有学者 [<xref ref-type="bibr" rid="hanspub.30278-ref9">9</xref>] 通过研究外泌体α–突触核蛋白的聚集动力学，发现外泌体可以与诱导形成α–突触核蛋白原纤维过程类似的方式诱导α–突触核蛋白的聚集。外泌体能够传播错误折叠蛋白并促进其发生病态聚集(随后将这些聚集体传送至中枢神经系统的无聚集区域)，而这些蛋白聚集体与疾病直接相关 [<xref ref-type="bibr" rid="hanspub.30278-ref3">3</xref>] ，从而加速神经系统变性进程，故外泌体又被称为神经变性的特洛伊木马 [<xref ref-type="bibr" rid="hanspub.30278-ref6">6</xref>] 。提示外泌体可以为α–突触核蛋白发生病态改变提供适宜的环境，从而参与PD的发生发展过程。</p><p>诸多研究表明神经炎症是PD等神经退行性疾病发生发展的因素之一 [<xref ref-type="bibr" rid="hanspub.30278-ref10">10</xref>] ，小胶质细胞、反应性星形胶质细胞等在静息状态下对机体起到一定的保护作用，但在长期慢性炎症激活下会有神经毒性，从而导致神经变性，而目前有些miRNA被认为属于广义的炎症介质并与神经变性有关，并有研究 [<xref ref-type="bibr" rid="hanspub.30278-ref11">11</xref>] 支持这种结论：miR-146a和miR-155可以抑制T滤泡辅助细胞的发育，从而调节体内慢性炎症的发生。另外研究 [<xref ref-type="bibr" rid="hanspub.30278-ref12">12</xref>] 发现miR-7和miR-153能与α–突触核蛋白mRNA的3′非编码区特异结合，调节该mRNA和α–突触核蛋白的表达水平，从而参与PD的发生。</p></sec><sec id="s6"><title>4. 外泌体及其miRNA在PD早期预警及诊断中的价值</title><p>目前关于PD相关致病基因的研究如火如荼，现已知18个基因位点(PARK1-PARK18)与PD相关。其中与PD常染色体隐性遗传相关的有 [<xref ref-type="bibr" rid="hanspub.30278-ref12">12</xref>] ：PARK2的基因Parkin、PARK7的DJ-1和PARK9的ATP13A2。与PD常染色体显性遗传相关的有 [<xref ref-type="bibr" rid="hanspub.30278-ref5">5</xref>] ：PARK1/PARK4的基因SCNA/α-synuclein，PARK8的LRRK2。且新发现的PD相关基因，如NUS1、GBA、SH3GL2、SCN3A等等 [<xref ref-type="bibr" rid="hanspub.30278-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.30278-ref14">14</xref>] 也已陆续报道。已知PD患者富含亮氨酸重复激酶2 (LRRK2)的mRNA表达与正常人无明显差别，但研究 [<xref ref-type="bibr" rid="hanspub.30278-ref15">15</xref>] 显示miR-205可直接靶向调控LRRK2的表达水平，原来miRNA可在基因表达的转录后水平发挥调控作用。但是关于miRNA与PD基因相关性的机制尚未有定论：有研究指出 [<xref ref-type="bibr" rid="hanspub.30278-ref16">16</xref>] miR-16-1通过调节热休克蛋白HSP70进而调控基因α–突触核蛋白的聚集，还有学者 [<xref ref-type="bibr" rid="hanspub.30278-ref17">17</xref>] 发现miR-34b/c消耗下调与PD相关基因DJ-1和Parkin的表达降低相关，而miR-34b/c的失调会导致线粒体功能等障碍来参与PD的发生发展，故尚需进一步研究探讨。miRNA如何能顺利通过血脑屏障(Blood-brain barrier, BBB)发挥上述作用：外泌体可以作为载体携带miRNA通过BBB，研究发现 [<xref ref-type="bibr" rid="hanspub.30278-ref18">18</xref>] 携带荧光素酶的外泌体能够在炎症条件下穿过脑微血管内皮细胞单层，但却不能在正常条件下穿过，并还有如下特性：1) 外泌体含有在致病状态期间表达的疾病特异性或失调的miRNA，并可从健康细胞中除去异常miRNA。2) 外泌体有可能通过转胞吞作用穿过血屏障，从而可较容易的清除内皮细胞层。3) 外泌体内的miRNA可免受细胞核糖核酸酶的降解。故在体内检测到外泌体中致病miRNA对于PD的诊断预警中存在一定价值。</p><p>LRRK2基因的变异在PD的发生发展中起到重要作用，并在PD重要的几种脑结构 [<xref ref-type="bibr" rid="hanspub.30278-ref19">19</xref>] 中表达，例如纹状体、海马、皮质、黑质，且通过尿液和CSF外泌体的蛋白质印迹分析确定了LRRK2在这些生物流体中存在 [<xref ref-type="bibr" rid="hanspub.30278-ref20">20</xref>] ，有尸检研究 [<xref ref-type="bibr" rid="hanspub.30278-ref21">21</xref>] 显示PD患者前额叶皮质中LRRK2蛋白水平较对照组增加，虽然PD患者不进行脑活检，但在CSF及尿液外泌体中LRRK2可反映其在脑中的表达变化情况，有研究 [<xref ref-type="bibr" rid="hanspub.30278-ref22">22</xref>] 证明LRRK2外泌体在神经元和巨噬细胞中释放并在CSF中循环，在关于PD人群的研究发现：PD患者的尿外泌体中LRRK2，α–突触核蛋白和DJ-1的水平高于非PD对照组 [<xref ref-type="bibr" rid="hanspub.30278-ref23">23</xref>] 。故可尝试通过检测尿液、CSF外泌体，并分析其中基因水平以期在PD早期进行预警。另外Fraser早期研究发现：PD组与对照组相比在尿外泌体中可观察到S1292磷酸化的升高 [<xref ref-type="bibr" rid="hanspub.30278-ref24">24</xref>] ，提示尿外泌体中的S1292磷酸化水平可能是PD的预测因子。然而Fraser后期实验发现：虽然PD中S1292磷酸化显著增加 [<xref ref-type="bibr" rid="hanspub.30278-ref25">25</xref>] ，但尿外泌体中的S1292磷酸化水平不是PD患者的绝对预测因子，因为在实验及对照组中这些测量的分布中可见部分重叠。</p><p>有研究 [<xref ref-type="bibr" rid="hanspub.30278-ref26">26</xref>] 表明升高的ATP13A2基因可降低细胞内α–突触核蛋白水平并增加外泌体中α–突触核蛋白外化大于3倍，而ATP13A2减少则降低外泌体α–突触核蛋白外化，故外泌体相关的α–突触核蛋白的增加可以解释PD患者黑质致密部存活神经元过度表达的ATP13A2，从而提出ATP13A2可以调控含有α–突触核蛋白的外泌体的发生，而关于含有α–突触核蛋白的外泌体，Alvarez-Erviti等 [<xref ref-type="bibr" rid="hanspub.30278-ref27">27</xref>] 提到这些外泌体可以有效地将α–突触核蛋白从过表达的SH-SY5Y细胞转移到正常的SH-SY5Y细胞中，并且还通过实验证明了外泌体在α突触核蛋白的释放及其在细胞之间的传递中的重要性。另有学者 [<xref ref-type="bibr" rid="hanspub.30278-ref28">28</xref>] 研究发现α–突触核蛋白能增加细胞分泌外泌体，是否存在正反馈机制，仍有待于进一步研究，目前有希望通过检测外泌体相关基因ATP13A2来对PD进行早期预警。</p></sec><sec id="s7"><title>5. 外泌体及其miRNA靶向治疗PD</title><p>血脑屏障是指脑毛细血管壁与神经胶质细胞形成的血浆与脑细胞之间的屏障和由脉络丛形成的血浆和脑脊液之间的屏障，其能够阻止某些物质(多半是有害的)进入脑组织，但也严重限制了大蛋白分子的通过，故导致很多因不能通过血脑屏障的药物无法治疗CNS疾病 [<xref ref-type="bibr" rid="hanspub.30278-ref29">29</xref>] 。随着科技的进步，利用纳米技术克服血脑屏障已经取得不错的进展，但仍有纳米毒性等问题阻碍其发展，而研究 [<xref ref-type="bibr" rid="hanspub.30278-ref2">2</xref>] 表明，外泌体可透过血脑屏障从体循环转移至中枢神经系统，并且外泌体由于具备双膜结构能抵抗血液中核糖核酸酶的攻击，另外外泌体有免疫豁免权 [<xref ref-type="bibr" rid="hanspub.30278-ref30">30</xref>] ，可以有效地降低药物清除率。因此外泌体可作为载体用于PD等神经退行性疾病的靶向治疗。</p><p>关于PD治疗的新方向诸多学者矛头对准了干细胞，近期日本学者运用灵长类动物模型的实验研究 [<xref ref-type="bibr" rid="hanspub.30278-ref31">31</xref>] 表明，人诱导多能干细胞(iPS细胞)衍生的多巴胺能祖细胞可用于治疗PD患者，2018年11月Nature杂志封面上提到日本京都大学研究人员已经开展了利用诱导iPS细胞治疗帕金森病的临床试验，向一名患者脑部移植了由iPS细胞培养的神经祖细胞，据悉按照计划，这次开展的临床试验将为７名患者进行移植。但干细胞存在致瘤性、靶向性欠佳等问题，有学者 [<xref ref-type="bibr" rid="hanspub.30278-ref32">32</xref>] 提出使用干细胞衍生的外泌体代替亲本干细胞进行治疗，并且具备以下优点：1) 外泌体可以靶向进入目标细胞，提高治疗的特异性，减少副作用。2) 外泌体能够透过血脑屏障，因此可以通过微创方法(例如血液、鼻内等方式)递送。3) 可以操纵外泌体内容物成分以满足特定的治疗需求。另有研究 [<xref ref-type="bibr" rid="hanspub.30278-ref33">33</xref>] 指出外泌体可以增强干细胞的治疗效果，并有学者通过实验 [<xref ref-type="bibr" rid="hanspub.30278-ref34">34</xref>] 发现人脱落乳牙牙髓干细胞来源的外泌体能够抑制6–羟基多巴胺诱导的多巴胺能神经元凋亡(约80%)，因此干细胞及其释放的外泌体为PD治疗开辟了一系列新选择。</p><p>有学者 [<xref ref-type="bibr" rid="hanspub.30278-ref35">35</xref>] 将装载多巴胺的外泌体靶向递送PD小鼠模型的大脑，发现比静脉内施用游离多巴胺的治疗功效好且全身毒性低，有学者 [<xref ref-type="bibr" rid="hanspub.30278-ref36">36</xref>] 发现小鼠外周注射含有α–突触核蛋白siRNA的外泌体，能显著降低脑中α–突触核蛋白mRNA及其蛋白的表达水平。过氧化氢酶是自然界中发现的最有效的抗氧化剂之一，已被证明 [<xref ref-type="bibr" rid="hanspub.30278-ref37">37</xref>] 在PD体外模型中可以拯救小脑细胞，因此若能将过氧化氢酶成功注入大脑，可能有助于PD治疗。通过室温孵育、皂甘透化、冻融循环、超声处理、挤压等方法将过氧化氢酶加载到外泌体中，经小鼠鼻内给药，在脑内检测出相当数量的含药外泌体值 [<xref ref-type="bibr" rid="hanspub.30278-ref38">38</xref>] 。另有研究 [<xref ref-type="bibr" rid="hanspub.30278-ref39">39</xref>] 将氧化铁纳米粒子和外泌体中的药物结合起来，通过施加磁场梯度靶向引导进入机体特定区域进行靶向治疗。最近的一篇综述提到微流控技术与外泌体相结合可用于疾病的靶向治疗 [<xref ref-type="bibr" rid="hanspub.30278-ref40">40</xref>] 。</p><p>由于外泌体的诸多特性，使其具备有作为载体递送药物对逆转PD病理及脑保护的治疗潜力，有望为PD治疗带来新希望。但在利用外泌体及其miRNA靶向治疗PD实际操作过程中依然困难重重，首先，外泌体分离方法丰富多样(超速离心法、超滤法、免疫磁珠法、微流控芯片技术、聚乙二醇沉淀法、超滤法等等)，但缺乏统一的分离标准，且上述的分离方法都有其局限性，无论哪种方法都不能将外泌体与其他细胞外囊泡亚群彻底分离。其次，目前大量实验均在体外或动物体内进行，这些大量的体外实验最后都要回归到体内实验来验证其相关功能。如何确定体内体外实验使用的外泌体及其miRNA合理剂量也是未来的研究需要探讨的问题。以及外泌体及其miRNA靶向治疗PD潜在的风险及副作用等问题，仍有待于将来进一步探讨。外泌体及其miRNA靶向治疗的PD从动物实验到临床应用仍有很长的路要走。</p></sec><sec id="s8"><title>6. 总结与展望</title><p>本文介绍了外泌体及其miRNA的来源、特性、参与PD发生发展的过程，并重点综述了外泌体及其miRNA在PD早期预警、诊断的价值及靶向治疗PD等方面的研究进展。虽然外泌体及其miRNA与PD的发生发展有着密切的关系，其众多特性可有助于其运用于PD的诊断及治疗，但目前在分离、检测、纯化和表征外泌体的技术上仍存在诸多不足，下一步研究者们需制定完善的外泌体研究技术和标准，为进一步探索更有效、更准确、更实用的外泌体及其miRNA参与PD调控及治疗的方法提供基础。综上所述，外泌体及其miRNA有望为精准医学未来的发展带来新曙光。</p></sec><sec id="s9"><title>基金项目</title><p>国家自然科学基金项目(81400957)；山东省医药卫生科技发展计划项目(2016WSA10008)；威海市自体免疫重点实验室开放基金项目(2018-KF003)。</p></sec><sec id="s10"><title>文章引用</title><p>白家赫,郑亚利,于永鹏. 外泌体及其microRNA与帕金森病相关研究进展Research Advances in Exosome and Their MicroRNA for Parkinson’s Disease[J]. 临床医学进展, 2019, 09(05): 650-656. https://doi.org/10.12677/ACM.2019.95098</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.30278-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Leggio, L., Vivarelli, S., L’Episcopo, F., et al. (2017) microRNAs in Parkinson’s Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches. International Journal of Molecular Sciences, 18, pii: E2698.  
&lt;br&gt;https://doi.org/10.3390/ijms18122698</mixed-citation></ref><ref id="hanspub.30278-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Gui, Y.X., Liu, H., Zhang, L.S., et al. (2015) Altered microRNA Pro-files in Cerebrospinal Fluid Exosome in Parkinson Disease and Alzheimer Disease. Oncotarget, 6, 37043-37053. &lt;br&gt;https://doi.org/10.18632/oncotarget.6158</mixed-citation></ref><ref id="hanspub.30278-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Sarko, D.K. and Mckinney, C.E. (2017) Exosomes: Origins and Therapeutic Potential for Neurodegenerative Disease. Frontiers in Neuroscience, 11, 82. &lt;br&gt;https://doi.org/10.3389/fnins.2017.00082</mixed-citation></ref><ref id="hanspub.30278-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Kelly, P.S., Breen, L., Gallagher, C., et al. (2015) Re-Programming CHO Cell Metabolism Using miR-23 Tips the Balance towards a Highly Productive Phenotype. Biotechnology Journal, 10, 1029-1040.  
&lt;br&gt;https://doi.org/10.1002/biot.201500101</mixed-citation></ref><ref id="hanspub.30278-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Qiu, L., Zhang, W., Tan, E.K., et al. (2014) Deciphering the Function and Regulation of microRNAs in Alzheimer’s Disease and Parkinson’s Disease. ACS Chemical Neuroscience, 5, 884. &lt;br&gt;https://doi.org/10.1021/cn500149w</mixed-citation></ref><ref id="hanspub.30278-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">De, T.J., Herschlik, L., Waldner, C., et al. (2015) Emerging Roles of Exosomes in Normal and Pathological Conditions: New Insights for Diagnosis and Therapeutic Applications. Frontiers in Immunology, 6, 203.  
&lt;br&gt;https://doi.org/10.3389/fimmu.2015.00203</mixed-citation></ref><ref id="hanspub.30278-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Stuendl, A., Kunadt, M., Kruse, N., et al. (2016) Induction of α-Synuclein Aggregate Formation by CSF Exosomes from Patients with Parkinson’s Disease and Dementia with Lewy Bodies. Brain, 139, 481-494.  
&lt;br&gt;https://doi.org/10.1093/brain/awv346</mixed-citation></ref><ref id="hanspub.30278-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Danzer, K.M., Kranich, L.R., Ruf, W.P., et al. (2012) Exosomal Cell-to-Cell Transmission of Alpha Synuclein Oligomers. Molecular Neurodegeneration, 7, 42. &lt;br&gt;https://doi.org/10.1186/1750-1326-7-42</mixed-citation></ref><ref id="hanspub.30278-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gaspar, R., Meisl, G., Buell, A.K., et al. (2017) Acceleration of α-Synuclein Aggregation. Amyloid, 24, 20-21.  
&lt;br&gt;https://doi.org/10.1080/13506129.2017.1292904</mixed-citation></ref><ref id="hanspub.30278-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Henning, U., Cristina, I., et al. (2015) Immunomodulation in Stem Cell Differentiation into Neurons and Brain Repair. Stem Cell Reviews and Reports, 11, 474-486. &lt;br&gt;https://doi.org/10.1007/s12015-014-9556-6</mixed-citation></ref><ref id="hanspub.30278-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Hu, R., Kagele, D.A., Huffaker, T.B., et al. (2014) MiR-155 Promotes T Follicular Helper Cell Accumulation during Chronic, Low-Grade Inflammation. Immunity, 41, 605-619. &lt;br&gt;https://doi.org/10.1016/j.immuni.2014.09.015</mixed-citation></ref><ref id="hanspub.30278-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Doxakis, E. (2010) Post-Transcriptional Regulation of α-Synuclein Expression by mir-7 and mir-153. Journal of Biological Chemistry, 285, 12726-12734. &lt;br&gt;https://doi.org/10.1074/jbc.M109.086827</mixed-citation></ref><ref id="hanspub.30278-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Guo, J.F., Zhang, L. and Li, K. (2018) Coding Mutations in NUS1 Contribute to Parkinson’s Disease. Proceedings of the National Academy of Sciences, 115, 11567-11572.</mixed-citation></ref><ref id="hanspub.30278-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Chang, D., Nalls, M.A., Hunkapiller, J., et al. (2017) A Meta-Analysis of Genome-Wide Association Studies Identifies 17 New Parkinson’s Disease Risk Loci. Nature Genetics, 49, 1511. &lt;br&gt;https://doi.org/10.1038/ng.3955</mixed-citation></ref><ref id="hanspub.30278-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Chen, Q., Huang, X. and Li, R. (2018) lncRNA MALAT1/miR-205-5p Axis Regulates MPP+-Induced Cell Apoptosis in MN9D Cells by Directly Targeting LRRK2. American Journal of Translational Research, 10, 563.</mixed-citation></ref><ref id="hanspub.30278-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Z. and Cheng, Y. (2014) miR-16-1 Promotes the Aberrant\r, α\r, -Synuclein Accumulation in Parkinson Disease via Targeting Heat Shock Protein 70. The Scientific World Journal, 2014, Article ID: 938348.  
&lt;br&gt;https://doi.org/10.1155/2014/938348</mixed-citation></ref><ref id="hanspub.30278-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Moyano, E.M., Porta, S., Escaramís, G., et al. (2011) MicroRNA Pro-filing of Parkinson’s Disease Brains Identifies Early Downregulation of miR-34b/c Which Modulate Mitochondrial Function. Human Molecular Genetics, 20, 3067-3078. &lt;br&gt;https://doi.org/10.1093/hmg/ddr210</mixed-citation></ref><ref id="hanspub.30278-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Kumar, S., Vi-jayan, M., Bhatti, J.S., et al. (2017) Chapter Three—MicroRNAs as Peripheral Biomarkers in Aging and Age-Related Diseases. Progress in Molecular Biology and Translational Science, 146, 47-94.  
&lt;br&gt;https://doi.org/10.1016/bs.pmbts.2016.12.013</mixed-citation></ref><ref id="hanspub.30278-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">West, A.B., Cowell, R.M., Daher, J.P.L., et al. (2014) Differ-ential LRRK2 Expression in the Cortex, Striatum, and Substantia Nigra in Transgenic and Nontransgenic Rodents. Journal of Comparative Neurology, 522, 2465-2480.  
&lt;br&gt;https://doi.org/10.1002/cne.23583</mixed-citation></ref><ref id="hanspub.30278-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Wang, S., Liu, Z., Ye, T., et al. (2017) Elevated LRRK2 Autophosphory-lation in Brain-Derived and Peripheral Exosomes in LRRK2 Mutation Carriers. Acta Neuropathologica Communications, 5, 86.  
&lt;br&gt;https://doi.org/10.1186/s40478-017-0492-y</mixed-citation></ref><ref id="hanspub.30278-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Riley, B.E., Gardai, S.J., Emig-Agius, D., et al. (2014) Sys-tems-Based Analyses of Brain Regions Functionally Impacted in Parkinson’s Disease Reveals Underlying Causal Mechanisms. PLoS ONE, 9, e102909.  
&lt;br&gt;https://doi.org/10.1371/journal.pone.0102909</mixed-citation></ref><ref id="hanspub.30278-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Fraser, K.B., Moehle, M.S., Daher, J.P., et al. (2013) LRRK2 Secretion in Exosomes Is Regulated by 14-3-3. Human Molecular Genetics, 22, 4988-5000. &lt;br&gt;https://doi.org/10.1093/hmg/ddt346</mixed-citation></ref><ref id="hanspub.30278-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Ho, D.H., Yi, S., Seo, H., et al. (2014) Increased DJ-1 in Urine Exosome of Korean Males with Parkinson’s Disease. Biomed Research International, 2014, Article ID: 704678. &lt;br&gt;https://doi.org/10.1155/2014/704678</mixed-citation></ref><ref id="hanspub.30278-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Fraser, K.B., Moehle, M.S., Alcalay, R.N., et al. (2016) Urinary LRRK2 Phosphorylation Predicts Parkinsonian Phenotypes in G2019S LRRK2 Carriers. Neurology, 86, 994-999. &lt;br&gt;https://doi.org/10.1212/WNL.0000000000002436</mixed-citation></ref><ref id="hanspub.30278-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Fraser, K.B., Rawlins, A.B., Clark, R.G., et al. (2016) Ser(P)-1292 LRRK2 in Urinary Exosomes Is Elevated in Idiopathic Parkinson’s Disease. Movement Disorders Official Journal of the Movement Disorder Society, 31, 1543-1550.  
&lt;br&gt;https://doi.org/10.1002/mds.26686</mixed-citation></ref><ref id="hanspub.30278-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Aitken, J., Lay, P., Park, J.S., et al. (2014) Parkinson’s Disease-Linked Human PARK9/ATP13A2 Maintains Zinc Homeostasis and Promotes Alpha-Synuclein Externalization via Exosomes. Human Molecular Genetics, 23, 2816.  
&lt;br&gt;https://doi.org/10.1093/hmg/ddu099</mixed-citation></ref><ref id="hanspub.30278-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Alvarez-Erviti, L., Seow, Y., Schapira, A.H., et al. (2011) Lysosomal Dysfunction Increases Exosome-Mediated Alpha-Synuclein Release and Transmission. Neurobiology of Disease, 42, 360-367.  
&lt;br&gt;https://doi.org/10.1016/j.nbd.2011.01.029</mixed-citation></ref><ref id="hanspub.30278-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Chang, C., Lang, H., Geng, N., et al. (2013) Exosomes of BV-2 Cells Induced by Alpha-Synuclein: Important Mediator of Neurodegeneration in PD. Neuroscience Letters, 548, 190-195. &lt;br&gt;https://doi.org/10.1016/j.neulet.2013.06.009</mixed-citation></ref><ref id="hanspub.30278-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Isra, Z., Anas, N. and Rafik, K. (2018) Strategies for Enhancing the Permeation of CNS-Active Drugs through the Blood-Brain Barrier: A Review. Molecules, 23, pii: E1289. &lt;br&gt;https://doi.org/10.3390/molecules23061289</mixed-citation></ref><ref id="hanspub.30278-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Lai, R.C., Yeo, R.W.Y., Tan, K.H., et al. (2013) Exosomes for Drug Delivery—A Novel Application for the Mesenchymal Stem Cell. Biotechnology Advances, 31, 543-551. &lt;br&gt;https://doi.org/10.1016/j.biotechadv.2012.08.008</mixed-citation></ref><ref id="hanspub.30278-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Tetsuhiro, K., Asuka, M., Daisuke, D., et al. (2017) Human iPS Cell-Derived Dopaminergic Neurons Function in a Primate Parkinson’s Disease Model. Nature, 548, 592-596. &lt;br&gt;https://doi.org/10.1038/nature23664</mixed-citation></ref><ref id="hanspub.30278-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Alejandro, L., Federico, B.L., Ursula, W., et al. (2016) Potential Therapies by Stem Cell-Derived Exosomes in CNS Diseases: Focusing on the Neurogenic Niche. Stem Cells International, 2016, Article ID: 5736059.  
&lt;br&gt;https://doi.org/10.1155/2016/5736059</mixed-citation></ref><ref id="hanspub.30278-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Chang, Y.H., Wu, K.C., Harn, H.J., et al. (2018) Exosomes and Stem Cells in Degenerative Disease Diagnosis and Therapy. Cell Transplantation, 27, 349-363.</mixed-citation></ref><ref id="hanspub.30278-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Jarmalavičiūtė, A., Tunaitis, V., Pivoraitė, U., et al. (2015) Exosomes from Dental Pulp Stem Cells Rescue Human Dopaminergic Neurons from 6-Hydroxy-Dopamine-Induced Apoptosis. Cytotherapy, 17, 932-939.  
&lt;br&gt;https://doi.org/10.1016/j.jcyt.2014.07.013</mixed-citation></ref><ref id="hanspub.30278-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Qu, M., et al. (2018) Dopamine-Loaded Blood Exosomes Targeted to Brain for Better Treatment of Parkinson’s Disease. Journal of Controlled Release, 287, 156-166.</mixed-citation></ref><ref id="hanspub.30278-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Cooper, J.M., Wiklander, P.B.O., Nordin, J.Z., et al. (2015) Systemic Exosomal siRNA Delivery Reduced Alpha-Synuclein Aggregates in Brains of Transgenic Mice. Movement Disorders Official Journal of the Movement Disorder Society, 29, 1476-1485. &lt;br&gt;https://doi.org/10.1002/mds.25978</mixed-citation></ref><ref id="hanspub.30278-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">González-Polo, R.A., Soler, G., Morán, J.M., et al. (2013) Protection against MPP+ Neurotoxicity in Cerebellar Granule Cells by Antioxidants. Cell Biology International, 28, 373-380. &lt;br&gt;https://doi.org/10.1016/j.cellbi.2004.03.005</mixed-citation></ref><ref id="hanspub.30278-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Haney, M.J., Klyachko, N.L., Zhao, Y., et al. (2015) Exosomes as Drug Delivery Vehicles for Parkinson’s Disease Therapy. Journal of Controlled Release Official Journal of the Controlled Release Society, 207, 18-30.  
&lt;br&gt;https://doi.org/10.1016/j.jconrel.2015.03.033</mixed-citation></ref><ref id="hanspub.30278-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Silva, A.K.A., Luciani, N., Gazeau, F., et al. (2015) Combining Magnetic Nanoparticles with Cell Derived Microvesicles for Drug Loading and Targeting. Nanomedicine Nano-technology Biology &amp; Medicine, 11, 645-655.  
&lt;br&gt;https://doi.org/10.1016/j.nano.2014.11.009</mixed-citation></ref><ref id="hanspub.30278-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Liu, C., Feng, Q. and Sun, J. (2018) Lipid Nanovesicles by Mi-crofluidics: Manipulation, Synthesis, and Drug Delivery. Advanced Materials. &lt;br&gt;https://doi.org/10.1002/adma.201804788</mixed-citation></ref></ref-list></back></article>